IBM Research Arm To Invest $1 Billion In India Trials, Drug-Safety Testing (India)
This article was originally published in PharmAsia News
Executive Summary
IBM T J Watson, the research arm of U.S. giant IBM, plans to invest up to $1 billion into pharmaceutical and health services in India, its manager says. In the drug-making area, up to 40 percent of the total investment is to be spent on clinical trials and contracting research space in India. Part of another 30 percent may go for technology to detect spurious drugs, J. Sairamesh said, noting Ranbaxy's recent U.S. recall of 73 million doses of its painkiller Gabapentin (gabapentin). (Click here for more